Aligos Therapeutics, Inc. ALGS

Company Overview

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for liver diseases and viral infections. The company operates within the biotechnology and pharmaceutical industries, with research efforts historically centered on chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH/NASH), and coronavirus-related antiviral programs. Aligos primarily generates value through research and development activities, intellectual property creation, licensing potential, and advancement of proprietary drug candidates through clinical development.

The company was founded in 2018 by a group of biotechnology executives and scientists with experience in antiviral and liver disease drug development. Aligos built its platform through internal drug discovery capabilities and licensed technologies, positioning itself as a specialized developer of liver-targeted therapeutics. The company has emphasized differentiated mechanisms of action, including small molecules aimed at viral replication, capsid assembly modulation, and liver disease pathways. Public disclosures indicate that the company has periodically restructured its portfolio and prioritized programs based on clinical data, capital allocation, and market conditions.